Furthermore, they evaluated the potential of four more proton pump inhibitors for their anti-proliferation activity on leukemia cells and confirmed that proton pump inhibitors selectively inhibit leukemia cells with MLL-rearrangements and not wild type leukemia cells or normal control cells (Chen et al., 2020). Here, KMT2A is linked to leukemia.